News

2015

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer

BIND Therapeutics 12.16.2015

BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

BIND Therapeutics 12.14.2015

BIND Therapeutics Expands Board of Directors with Appointment of Dr. Arthur Tzianabos

BIND Therapeutics 10.14.2015

bBIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors

BIND Therapeutics 09.24.2015

BIND Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update

BIND Therapeutics 08.06.2015

BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811

BIND Therapeutics 06.23.2015

BIND Therapeutics and Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform

BIND Therapeutics 06.12.2015

Loading